Table 2 Characteristics of included studies
Author | Year | Indication | Treatment group | Control group | Control intervention | Study duration | ||
|---|---|---|---|---|---|---|---|---|
N | Age | N | Age | |||||
Derosa [36] | 2013 | Dyslipidaemia | 51 | 52 ± 10.5 | 47 | 52 ± 10.5 | Placebo | 3 months |
Derosa [37] | 2013 | Dyslipidaemia | 52 | 51.4 ± 9.5 | 50 | 51.4 ± 9.5 | Placebo | 3 months |
Pierro [38] | 2013 | Type 2 diabetes | 32 | 67.85 ± 10.81 | 31 | 66.35 ± 9.8 | B. aristata supplement | 4 months |
Derosa [39] | 2015 | Dyslipidaemia | 66 | 57.8 ± 12.6 | 62 | 57.9 ± 12.9 | Placebo | 3 months |
Guarino [40] | 2015 | Obese + type 2 diabetes | 25 | 54 ± 5 | 25 | 56 ± 7 | Placebo | 6 months |
Derosa [41] | 2016 | Type 1 Diabetes | 41 | 30.7 ± 8.1 | 44 | 29.8 ± 7.2 | Placebo | 6 months |
Guarino [42] | 2017 | Obese + type 2 diabetes | 68 | 56 ± 8 | 68 | 55 ± 9 | Placebo | 52 weeks |